Novel Experimental COVID-19 Therapies Affecting Host Response Read more about Novel Experimental COVID-19 Therapies Affecting Host Response
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) Read more about Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies Read more about An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection Read more about Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis Read more about COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Read more about Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Read more about A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 Read more about ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants. Read more about A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.